To The Moon

Since the Fed started hiking interest rates in 2022, pharma stocks in the US market haven't been the talk of the town. Their reliance on high-risk innovations to create shareholder value is the core reason.But $AbbVie(ABBV)$ , a pharma stock, is an outlier. Over the past 12 months, its total return, including dividends, has hit 30%, even outpacing the $S&P 500(.SPX)$ 's over 27%.Now, the question is, can this pharma stock keep outperforming the market?Despite AbbVie's strong recent performance, its forward P/E ratio is still just 15.2, significantly lower than the S&P 500's 22.6.Why is AbbVie's stock so cheap? Well, it's undergoing a transformation in its product portfolio. With the sharp drop in

$Rivian Automotive, Inc.(RIVN)$ Key arguments in support of the idea.• The Company’s supplies grow faster than on average in the market.• Modernization and expansion of production lines may lead to a boom in sales in2025.Investment ThesisRivian Automotive, Inc. (RIVN) is a US company that develops, manufactures and sells electric vehicles. The model range is presented by electric SUVs of the R series. The Company is also developing its own line of commercial vans, EDV, actively used by Amazon.com, Inc. for delivery in 100+ US cities. The retail giant is also one of Rivian’s major investors.The Company’s EV shipments grow faster than in the industry on average. In Q1, sales of BEVs in the United States increased by only 2%